Sunshine Biopharma Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation CO
Business Address 333 LAS OLAS WAY, FORT LAUDERDALE, FL, 33301
Mailing Address 333 LAS OLAS WAY, FORT LAUDERDALE, FL, 33301
Phone 954-330-0684
Fiscal Year End 1231
EIN 205566275
Financial Overview
FY2024
$30.56M
Total Assets
$7.06M
Total Liabilities
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | February 20, 2026 | View on SEC |
| 8-K Current report of material events | February 5, 2026 | View on SEC |
| 8-K Current report of material events | December 12, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 13, 2025 | View on SEC |
| DEF 14A Definitive proxy statement | October 23, 2025 | View on SEC |
| 8-K Current report of material events | September 30, 2025 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | August 14, 2025 | View on SEC |
| 10-Q Quarterly financial report | August 12, 2025 | View on SEC |
| S-1 IPO registration statement | August 5, 2025 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | June 12, 2025 | View on SEC |
Material Events
8-K Strategy Change February 20, 2026
High Impact
- Reverse stock split approved to maintain Nasdaq listing and meet minimum bid price requirements.
- Aims to boost per-share trading price, potentially enhancing stock appeal and liquidity.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.